SCHEMBL3250683

SCHEMBL3250683

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)NCC4CCNC4)cc3c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.36
TP53 P04637 3/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 6/20 0.36
THRB P10828 1/20 0.36
KDM4E B2RXH2 5/20 0.35
HSD17B10 Q99714 4/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
MAPK1 P28482 2/20 0.35
ALOX15 P16050 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GABRA1 P14867 2/20 0.35
GABRB2 P47870 2/20 0.35
KDM1A O60341 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRA3 P34903 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14877668 1.00 MAPT (0.36) MAPTTP53LMNAPOLBTHRB
SCHEMBL3243070 0.95 HTR4 (0.39) MAPTTP53LMNAPOLBTHRB
SCHEMBL3248398 0.88 POLB (0.40) POLBKDM4EHSD17B10MEN1KMT2A
SCHEMBL3254905 0.85 PARG (0.45) MAPTTP53LMNAPOLBTHRB
SCHEMBL3248963 0.84 TAS2R14 (0.44) MAPTTP53LMNATHRBKDM4E
SCHEMBL3245352 0.83 HTR2C (0.42) POLBKDM4EHSD17B10MEN1KMT2A
SCHEMBL3250602 0.83 PARG (0.50) MAPTTP53LMNAPOLBTHRB
SCHEMBL3249464 0.82 HTR2C (0.38) MAPTTP53LMNAPOLBKDM4E
SCHEMBL3247256 0.81 TDP1 (0.53) MAPTTP53LMNAPOLBTHRB
SCHEMBL3250480 0.81 TDP1 (0.53) MAPTTP53LMNAPOLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 MAPT 734/4885TP53 637/4885LMNA 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.